

05/17/05

MODIFIED PTO/SB/08 (08-09)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/019,071
Date Submitted: May 17, 2005		Filing Date	5/15/2002
(use as many sheets as necessary)		First Named Inventor	BRONNER, Christian
Sheet	1	of	2
		Group Art Unit	1842
		Examiner Name	Minh-Tam DAVIS
		Attorney Docket Number	065691-0266

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
VS	A1	WO	98 37207	A	Hickson et al.	08-27-1998	
VS	A2	WO	99 38971	A	Crkvenjakov et al.	08-05-1999	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
V.S.	A3	DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES, "Homo sapiens cDNA clone IMAGE: 1750886 3' similar to TR:015871 015871 UBIQUITIN, rRNA sequence", XP002133353 (Aug. 18, 1998).	
	A4	DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES, "Homo sapiens cDNA 5", clone IMAGE: 1750886 3' similar to TR:015871 015871 UBIQUITIN, Rrna sequence, XP002133354 (Apr. 18, 1997).	
	A5	DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES, "Homo sapiens chromosome 19 clone CTC-518P12, Working Draft Sequence, 84 unordered pieces, XP002148667 (Apr. 3, 2000).	
	A6	FUJIMORI, A., et al., "Cloning and mapping of Np96 gene which encodes a novel nuclear protein associated with cell proliferation", MAMMALIAN GENOME, vol. 9, no. 12, pp. 1032-1035 (1998) (XP 000890078).	
	A7	HERZOG, C. E., et al., "Evaluation of a potential regulatory role for inverted CCAAT boxes in the human topoisomerase IIalpha promoter", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 232, pp. 608-612 (1997) (XP000877157).	
al	A8	HOPFNER, R., et al., "ICBP90, a novel human CCAAT binding protein, involved in the regulation of topoisomerase IIalpha expression", CANCER RESEARCH, vol. 60, no. 1, pp. 121-128 (Jan. 1, 2000) (XP0008884566).	
↓	A9	ISAACS, R. J., et al., "Regulation of the human topoisomeraase IIalpha gene promoter in confluence arrested cells", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 28, pp. 16741-16747 (Jul. 12, 1996) (XP002133355).	

Examiner Signature	M. T. Davis	Date Considered	27/5/05
-----------------------	-------------	--------------------	---------

'EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: May 17, 2005 <i>(use as many sheets as necessary)</i>				Complete If Known	
Sheet	2	of	2	Application Number	10/019,071
				Filing Date	5/15/2002
				First Named Inventor	BRONNER, Christian
				Group Art Unit	1642
				Examiner Name	Minh-Tam DAVIS
				Attorney Docket Number	065691-0266

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
TM	A10	KUBO, T., et al., "DNA topoisomerase IIalpha gene expression under transcriptional control in etoposide/teniposide-resistant human cancer cells". CANCER RESEARCH, vol. 55, pp. 3860-3864 (Sept. 1, 1995) (XP000877419).	
	A11	LIM, K., et al., "Reduced level of ATF is correlated with transcriptional repression of DNA topoisomerase IIalpha gene during TPA-induced differentiation HL-60 cells", BIOCHEMISTRY AND MOLECULAR BIOLOGY INTL., vol. 46, no. 1, pp. 35-42 (Sept. 1, 1998) (XP000800088).	
	A12	SANDRI, M. I., et al., "P53 Regulates the minimal promoter of the human nucleic acids research, GB, Oxford University Press, Surrey, vol. 24, no. 22, pp. 4464-4470 (Nov. 15, 1996) (XP002068824).	
	A13	SEQ ID NO. 944, pp. 5-6 and 55-57. <i>for what publication?</i> <i>Year? date?</i> <i>reviewed but</i> <i>cannot be published</i> <i>TM</i>	

Examiner Signature	M.T. DAVIS	Date Considered	07/25/05
--------------------	------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.